Form 4: Vertex Pharma EVP Sells Shares Under 10b5-1 Plan

Vertex Pharmaceuticals' EVP, Chief Regulatory & Quality Officer, Ourania Tatsis, sold shares totaling $215,000 under a pre-arranged 10b5-1 trading plan.

Summary

• Ourania Tatsis, Executive Vice President, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals Inc. (VRTX), reported transactions involving common stock.
• On February 10, 2026, 2,140 shares of common stock were disposed of at a price of $468.41 per share, likely for tax withholding purposes, totaling approximately $1,000,497.
• On February 11, 2026, 466 shares of common stock were sold at a price of $460.43 per share, totaling approximately $214,530.
• These transactions were made pursuant to Dr. Tatsis' company-approved trading plan under Rule 10b5-1, which was established on August 21, 2025.
• Following these transactions, Dr. Tatsis beneficially owns 51,436 shares of Vertex Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transactions are routine insider sales and tax withholdings conducted under a pre-arranged 10b5-1 plan, which mitigates any negative sentiment typically associated with insider selling.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are common for executives as part of their compensation and personal financial planning. The use of a Rule 10b5-1 plan indicates a pre-scheduled transaction, which is a standard practice to avoid accusations of trading on material non-public information.

Comparison to Industry Standards

• Insider sales under Rule 10b5-1 plans are a common practice across the pharmaceutical and biotechnology industries, aligning with corporate governance best practices to manage executive stock ownership and compensation in a compliant manner.
• The volume of shares sold by Dr. Tatsis is relatively small compared to her total beneficial ownership, which is typical for routine liquidity events or tax obligations rather than a significant divestment.

Stakeholder Impact

• Shareholders: The sale of shares by an executive under a 10b5-1 plan is a routine event and typically has minimal direct impact on shareholder value or perception, as it is pre-scheduled and not indicative of a change in company outlook.

Key Dates

Recommendation

The reported transactions are routine insider sales and tax withholdings executed under a pre-established 10b5-1 trading plan. Such planned sales are not typically indicative of management's view on the company's future prospects and therefore do not warrant a change in investment recommendation based solely on this filing. Investors should continue to evaluate Vertex Pharmaceuticals based on its fundamental performance, pipeline, and market position.

Keywords

Vertex Pharmaceuticals, VRTX, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Executive Compensation